HOUSTON--(BUSINESS WIRE)--
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that three abstracts on the Company’s lead product candidate, BPX-501, including an oral presentation by Dr. Neena Kapoor, to review results from a study of pediatric patients with immune deficiencies, were accepted for presentation at the 58th American Society of Hematology (ASH) Annual Meeting. The Company will also present data highlighting preclinical results from the application of its GoCAR-T and GoTCR technologies in two poster presentations. ASH 2016 is being held in San Diego, California on December 3-6.
Investor/Analyst Luncheon
Bellicum will host an investor and analyst luncheon on Monday, December 5, 2016 at 12:15 PM -1:15 PM PST at the San Diego Marriott Gaslamp Quarter Hotel. Management and investigators Dr. Franco Locatelli (Ospedale Pediatrico Bambino Gesù), Dr. Neena Kapoor (Children’s Hospital of Los Angeles), and Dr. Kris Mahadeo (Montefiore Medical Center) will discuss BPX-501 Phase 2 clinical data in the malignant and non-malignant setting. The luncheon will be webcast live and may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.
ASH Presentations on Bellicum Programs
BPX-501:
Oral Presentation: “Outcome of Children with Primary Immune-Deficiencies (PIDs) Enrolled in a Phase I-II Trial Based on the Infusion of BPX-501 Donor T Cells Genetically Modified with a Novel Suicide Gene (Inducible Caspase 9, iC9) After T-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (Haplo-HSCT)”
Abstract Number: 72
Session Name: 732.Clinical
Allogeneic Transplantation: Results: Predicting Outcome
Date:
Saturday, December 3, 2016
Session Time: 7:30 AM - 9:00 AM
PST
Presentation Time: 8:45 AM PST
Poster Presentation: “T-Cell Depleted HLA-Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (Haplo-HSCT) Followed by Donor Lymphocyte Infusion with T Cells Transduced with the Inducible Caspase 9 (iC9) Suicide Gene in Children with Hematological Malignancies”
Abstract Number: 4683
Session Name: 732.Clinical
Allogeneic Transplantation: Results: Poster III
Date:
Monday, December 5, 2016
Presentation Time: 6:00 PM - 8:00
PM PST
Poster Presentation: “Clinical Outcome and Immune Recovery after Adoptive Infusion of BPX-501 Cells (Donor T Cells Transduced with iC9 Suicide Gene) in Children with Hemoglobinopathies and Diamond-Blackfan Anemia Given a/b T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (HSCT)”
Abstract Number: 2286
Session Name: 732.Clinical
Allogeneic Transplantation: Results: Poster I
Date:
Saturday, December 3, 2016
Presentation Time: 5:30 PM - 7:30
PM PST
CAR-T Program: (CD123 CARs)
Poster Presentation: “Inducible MyD88/CD40 (iMC) Costimulation Provides Ligand-Dependent Tumor Eradication by CD123-Specific Chimeric Antigen Receptor T Cells”
Abstract Number: 4551
Session Name: 703.Adoptive
Immunotherapy: Poster III
Date: Monday, December 5, 2016
Presentation
Time: 6:00 PM – 8:00 PM PST
TCR Program: (PRAME and Bob-1 TCRs)
Poster Presentation: “Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells and Improves Anti-Tumor Efficacy in Myeloma”
Abstract Number: 4550
Session Name: 703.Adoptive
Immunotherapy: Poster III
Date: Monday, December 5, 2016
Presentation
Time: 6:00 PM – 8:00 PM PST
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161103005919/en/
